Test mezigdomide vs pomalidomide with standard drugs for myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple myeloma, with measurable signs of the disease on specific lab tests (blood or urine), or high abnormal free light chains.
- You have had 1 to 3 prior treatments for myeloma.
- After at least one prior treatment, you had a minimal response (MR) or better, meaning the disease shrank or improved on that therapy.
- Your disease has not clearly progressed during treatment, or within 60 days after your last proteasome inhibitor dose (with some specific exceptions for certain maintenance schedules).
- You have not previously been treated with mezigdomide or pomalidomide.
- If you previously took a bortezomib-containing regimen, you must not have stopped due to side effects or had less-than-minimal response (MR or better).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of an injected drug (etentamig) and a pill (pomalidomide) compared to standard treatments for people whose multiple myeloma has returned or stopped responding to earlier therapies. The goal is to see if this new approach works better and has manageable side effects.
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
This trial studies whether a combination of three medicines (leflunomide, pomalidomide, and dexamethasone) can better treat multiple myeloma that has come back or stopped responding. It may help people who are not good candidates for transplant and who have measurable disease.
This trial tests a combination of three drugs (mezigdomide, carfilzomib, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug mix can help control the cancer again.
This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.